<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03894657</url>
  </required_header>
  <id_info>
    <org_study_id>P170907J</org_study_id>
    <secondary_id>2018-002624-16</secondary_id>
    <nct_id>NCT03894657</nct_id>
  </id_info>
  <brief_title>Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi®.</brief_title>
  <acronym>PREDICT-CF</acronym>
  <official_title>Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi®. Pathway to Personalized Therapy in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate whether the correction of CFTR function by&#xD;
      Lumacaftor/Ivacaftor in a patient-derived primary nasal cell model is a surrogate biomarker&#xD;
      for respiratory improvement in Orkambi® treated patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Orkambi® is a combination of Ivacaftor (a CFTR channel potentiator) and Lumacaftor (a&#xD;
      corrector partially rescuing the traffic of mutated CFTR). This treatment is now marketed in&#xD;
      France for patients homozygotes for the mutation p.Phe508del, aged 12 and above. Systematic&#xD;
      use of this product is a concern due to the lack of predictive markers of efficacy, the&#xD;
      highly variable respiratory improvement in patients and potential serious side effects.&#xD;
&#xD;
      The purpose of this study is to investigate the predictive value for improvement of the&#xD;
      respiratory function after 24 weeks of Orkambi treatment of an in vitro test. This test&#xD;
      quantifies the correction of CFTR activity as assessed by the change of cyclic AMP (cAMP)&#xD;
      dependant chloride (Cl-) secretion in patient derived Human Nasal Epithelial (HNE) derived&#xD;
      primary culture after Lumacaftor/Ivacaftor 48 hours incubation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2019</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of FEV1</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Absolute change in the percentage of predicted forced expiratory volume in 1 second (%FEV1) from baseline to week 24 of Orkambi®</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Z-score of FEV1</measure>
    <time_frame>Baseline, Week 24, week 48</time_frame>
    <description>Absolute change in the Z-score of forced expiratory volume in 1 second (FEV1) from baseline to week 24 and to week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of FEV1</measure>
    <time_frame>Week 48</time_frame>
    <description>Absolute change in the percentage of predicted forced expiratory volume in 1 second (FEV1) from baseline through week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of FVC</measure>
    <time_frame>Baseline, Week 24 and week 48</time_frame>
    <description>Absolute change in percent predicted of forced vital capacity (%FVC) from baseline through week 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of RFC</measure>
    <time_frame>Baseline, Week 24 and week 48</time_frame>
    <description>Absolute change in percent predicted of Functional Residual Capacity (%RFC) from baseline through week 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung clearance index</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Absolute change in lung clearance index 2.5 (LCI2.5) from baseline through Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height</measure>
    <time_frame>Baseline, Week 24 and week 48</time_frame>
    <description>Absolute change in height-for-age-z-score from baseline to week 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Baseline, Week 24 and week 48</time_frame>
    <description>Absolute change in weight-for-age-z-score from baseline to week 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>colony forming unit (CFU)</measure>
    <time_frame>Baseline, Week 24 and week 48</time_frame>
    <description>Absolute change in colony forming unit (CFU) of sputum microorganisms from baseline to week 24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of exacerbations</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Number of exacerbations to week 48 in comparison to the year previous treatment with Orkambi®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sweat Cl-</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Absolute change in sweat Cl- from baseline to week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level in Forskolin/IBMXdependant Short Circuit Current</measure>
    <time_frame>Baseline</time_frame>
    <description>Level in Forskolin/IBMXdependant Short Circuit Current change in patient nasal epithelial (HNE) cells incubated with Lumacaftor/Ivacaftor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of cells displaying apical staining</measure>
    <time_frame>baseline</time_frame>
    <description>Correction of CFTR expression at the apical membrane in HNE cells incubated with Lumacaftor/Ivacaftor, assessed by the percentage of cells displaying apical staining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of Lumacaftor/Ivacaftor</measure>
    <time_frame>Week 24, week 48</time_frame>
    <description>Pharmacokinetic parameters of Lumacaftor, M28-lumacaftor, Ivacaftor, M1-ivacaftor, and M6-ivacaftor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug concentrations of Lumacaftor/Ivacaftor</measure>
    <time_frame>Week 24, week 48</time_frame>
    <description>Pharmacokinetic parameters of Lumacaftor, M28-lumacaftor, Ivacaftor, M1-ivacaftor, and M6-ivacaftor</description>
  </secondary_outcome>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Homozygous F508del Mutation</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Nasal brushing</intervention_name>
    <description>Nasal scrapping at visit V0</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sputum sample</intervention_name>
    <description>Visit V0 : 1 Aliquot for Sputum biobank&#xD;
Visit V1 : 2 Aliquots&#xD;
for Sputum biobank&#xD;
for pharmacokinetic (PK) study&#xD;
Visit V2 : 2 Aliquots&#xD;
for Sputum biobank&#xD;
for pharmacokinetic (PK) study</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>Visit V0 : Additional 14 mL&#xD;
5 mL in ethylenediaminetetraacetic acid (EDTA) tube for DNA Analysis&#xD;
3 mL in Dry tube for Serum biobank&#xD;
6 mL in acid citrate dextrose (ACD) tube for peripheral blood mononuclear cell (PBMC) biobank&#xD;
Visit V1 : Additional 9 mL&#xD;
2x3 mL in dry tube for pharmacokinetic (PK) study&#xD;
3 mL in Dry tube for Serum biobank&#xD;
Visit V2 : Additional 6 mL&#xD;
3 mL in dry tube for pharmacokinetic (PK) study&#xD;
3 mL in Dry tube for Serum biobank</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orkambi</intervention_name>
    <description>Study the predictive value for improvement of the respiratory function after 24 weeks of Orkambi treatment.&#xD;
Orkambi treatment is part of usual care.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Homozygous F508del patient aged 5 years or older&#xD;
&#xD;
          -  Patient with an indication for Orkambi® treatment according to the marketing&#xD;
             authorization application&#xD;
&#xD;
          -  Patient never received Orkambi® in the past&#xD;
&#xD;
          -  Patient able to perform FEV1&#xD;
&#xD;
          -  Signed Informed consent form by the patient (if aged ≥ 18 years), or by parents /&#xD;
             legal guardian and patient's agreement (if aged &lt; 18 years) Patient affiliated to the&#xD;
             health insurance system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Homozygous F508del patients who do not meet the treatment indications according to the&#xD;
             marketing authorization application&#xD;
&#xD;
          -  Patients refusing Orkambi®&#xD;
&#xD;
          -  CF patients not homozygous for the p.Phe508del mutation&#xD;
&#xD;
          -  Active smoker&#xD;
&#xD;
          -  Severe nasal mucosa disrepair&#xD;
&#xD;
          -  Contraindications to xylocaine anesthesia,&#xD;
&#xD;
          -  Participation with another interventional study with drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ISABELLE SERMET, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Necker Enfants Malades</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ISABELLE SERMET, PhD</last_name>
    <phone>+33 1 44 49 48 87</phone>
    <email>isabelle.sermet@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laure CHOUPEAUX, MASTER</last_name>
    <phone>+33 1 44 38 17 11</phone>
    <email>laure.choupeaux@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <state>ILE DE France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ISABELLE SERMET, PhD</last_name>
      <phone>: +33 1 44 49 48 87</phone>
      <email>isabelle.sermet@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CYSTIC FIBROSIS</keyword>
  <keyword>ORKAMBI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

